EYLEA HD is anticipated to gain traction with the launch of a prefilled syringe in mid-2025 and label expansions for macular edema and extended dosing intervals. Management believes these developments ...

A 58-year-old male patient presented to the dermatology clinic at West China Hospital of Sichuan University (Chengdu, Sichuan ...

This entity was first described by Chorzelski and Jablonska from Warsaw Center of Bullous Diseases ... We as a first published a case of anti-p200kD pemphigoid mediated by IgA. Our immunoelectron ...

Dupilumab is under clinical development by Regeneron Pharmaceuticals and currently in Phase III for Bullous Pemphigoid. According to GlobalData, Phase III drugs for Bullous Pemphigoid does not have ...

In BP, DIF shows C3 and IgG deposition, whereas C3 and IgA deposits are present in linear IgA dermatosis. 11,12 Furthermore, bullous pemphigoid has a predominantly eosinophilic infiltrate, while ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Chances of developing various autoimmune diseases ...

AISBD in dogs and cats include mucous membrane pemphigoid, epidermolysis bullosa aquisita, and bullous pemphigoid. These can be diagnosed via recognition of histopathologic features, detailed medical ...

RAY-121 is under development for the treatment of autoimmune disease, antiphospholipid syndrome (APS), bullous pemphigoid (BP), Behçet's Syndrome (BS), dermatomyositis (DM), immune-mediated ...

Ocular cicatricial pemphigoid (OCP) is a rare autoimmune disease. Without proper treatment, it can damage the eyes and cause vision loss. OCP is a type of mucous membrane pemphigoid (MMP).